GDF15 and hematologic disorder: Further studies are needed to assess the value of GDF15 as a new biomarker for evaluating treatment response and monitoring disease progression in hematologic malignancies including PMF, and to understand the precise roles of this cytokine in the BM microenvironment in both physiological and pathological conditions.